TY - JOUR
T1 - Cardiovascular effects of intraosseous injections of 2 percent lidocaine with 1:100,000 epinephrine and 3 percent mepivacaine
AU - Replogle, Karan
AU - Reader, Al
AU - Nist, Robert
AU - Beck, Mike
AU - Weaver, Joel
AU - Meyers, William J.
N1 - Funding Information:
This study was supported by the Graduate Endodontic Research Fund and the Dr. Steven Goldberg Memorial Fund through the College of Dentistry, The Ohio State University. 1. Leonard MS. The efficacy of an in- traosseous injection system of delivering local anesthetic. JADA 1995;126:81-6. 2. Coggins R, Reader A, Nist R, Beck M, Meyers W. Anesthetic efficacy of the in traosseous injection in maxillary and mandibular teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:634-41. 3. Replogle K, Reader A, Nist R, Beck M, Weaver J, Meyers W. Anesthetic efficacy of the intraosseous injection of 2% lidocaine (1:100,000 epinephrine) and 3% mepivacaine in mandibular first molars. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:30-7. 4. Dunbar D, Reader A, Nist R, Beck M, Meyers W. Anesthetic efficacy of the in traosseous injection after an inferior alveolar nerve block. J Endod 1996;22:481-6. 5. Nusstein J, Reader A, Nist R, Beck M, Meyers W. Anesthetic efficacy of the supplemental intraosseous injection of 2% lidocaine with 1:100,000 epinephrine in irreversible pulpitis. J Endod 1998;24:487-91. 6. Reisman D, Reader A, Nist R, Beck M, Weaver J. Anesthetic efficacy of the supplemental intraosseous injection of 3% mepivacaine in irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:676-82.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1999/5
Y1 - 1999/5
N2 - Background. Because a number of patients have reported an increase in heart rate with the intraosseous, or IO, injection, it is important to evaluate changes in the cardiovascular system with this injection technique. The purpose of this study was to determine the cardiovascular effects of an IO injection of 2 percent lidocaine with 1:100,000 epinephrine and 3 percent mepivacaine. Methods. With the use of a repeated-measures design, the authors randomly assigned 42 subjects to receive IO injections of 1.8 milliliters of 2 percent lidocaine with 1:100,000 epinephrine or 1.8 mL of 3 percent mepivacaine in a double-blinded manner at two appointments. At each appointment, the authors monitored electrocardiographic findings, cardiac rate, systolic and diastolic blood pressure, and mean arterial pressure before, during and after administration of anesthetic solutions. Results. With the 2 percent lidocaine with 1:100,000 epinephrine solution, 28 (67 percent) of 42 subjects experienced an increase in heart rate that might be attributed to the effect of the epinephrine. In 22 (79 percent) of these subjects, the heart rate returned to within 5 beats of baseline values within four minutes after solution deposition. The authors found no significant increase in heart rate in subjects receiving the 3 percent mepivacaine. No significant differences (P > .05) were found in mean diastolic, mean systolic or mean arterial blood pressure values between the subjects receiving 2 percent lidocaine with 1:100,000 epinephrine and those receiving 3 percent mepivacaine. Conclusions. The majority of subjects receiving the IO injection of the 2 percent lidocaine-epinephrine solution experienced a transient increase in heart rate. No significant increase in heart rate was seen with the IO injection of 3 percent mepivacaine. Clinical Implications. While patients would likely notice the heart rate increase with the lidocaine-epinephrine solution, it would not be clinically significant in most healthy patients. In patients whose medical condition, drug therapies or epinephrine sensitivity suggests caution, 3 percent mepivacaine is a good alternative for IO injections.
AB - Background. Because a number of patients have reported an increase in heart rate with the intraosseous, or IO, injection, it is important to evaluate changes in the cardiovascular system with this injection technique. The purpose of this study was to determine the cardiovascular effects of an IO injection of 2 percent lidocaine with 1:100,000 epinephrine and 3 percent mepivacaine. Methods. With the use of a repeated-measures design, the authors randomly assigned 42 subjects to receive IO injections of 1.8 milliliters of 2 percent lidocaine with 1:100,000 epinephrine or 1.8 mL of 3 percent mepivacaine in a double-blinded manner at two appointments. At each appointment, the authors monitored electrocardiographic findings, cardiac rate, systolic and diastolic blood pressure, and mean arterial pressure before, during and after administration of anesthetic solutions. Results. With the 2 percent lidocaine with 1:100,000 epinephrine solution, 28 (67 percent) of 42 subjects experienced an increase in heart rate that might be attributed to the effect of the epinephrine. In 22 (79 percent) of these subjects, the heart rate returned to within 5 beats of baseline values within four minutes after solution deposition. The authors found no significant increase in heart rate in subjects receiving the 3 percent mepivacaine. No significant differences (P > .05) were found in mean diastolic, mean systolic or mean arterial blood pressure values between the subjects receiving 2 percent lidocaine with 1:100,000 epinephrine and those receiving 3 percent mepivacaine. Conclusions. The majority of subjects receiving the IO injection of the 2 percent lidocaine-epinephrine solution experienced a transient increase in heart rate. No significant increase in heart rate was seen with the IO injection of 3 percent mepivacaine. Clinical Implications. While patients would likely notice the heart rate increase with the lidocaine-epinephrine solution, it would not be clinically significant in most healthy patients. In patients whose medical condition, drug therapies or epinephrine sensitivity suggests caution, 3 percent mepivacaine is a good alternative for IO injections.
UR - http://www.scopus.com/inward/record.url?scp=0033125285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033125285&partnerID=8YFLogxK
U2 - 10.14219/jada.archive.1999.0274
DO - 10.14219/jada.archive.1999.0274
M3 - Article
C2 - 10332129
AN - SCOPUS:0033125285
SN - 0002-8177
VL - 130
SP - 649
EP - 657
JO - Journal of the American Dental Association
JF - Journal of the American Dental Association
IS - 5
ER -